AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01298908 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Foam sclerotherapy
Description: Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
Study NCT02373085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic adjusted to antibiogram
Description: A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
Study NCT00002744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Study NCT00002744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00002744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study NCT00002744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Study NCT00002744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00422084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine artesunate
Description: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
Study NCT00422084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem® (artemether lumefantrine)
Description: AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
Study NCT01757990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of Stevioside and Rebaudioside on plaque pH
Description: After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
Study NCT01757990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Effect of Stevioside and Rebaudioside on plaque pH
Description: After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
Study NCT00002744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT02419508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
Study NCT02419508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brinz/brim vehicle
Description: Inactive ingredients used as a placebo for masking purposes
Study NCT02419508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue
Study NCT02419508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prostaglandin analogue
Study NCT03152682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GoodIdea
Description: Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
Study NCT03152682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
Study NCT03789227 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ganglion impar block
Description: the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
Study NCT03789227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ganglion impar block
Description: the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
Study NCT03782935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prenatal multivitamin mineral supplement
Description: prenatal vitamin/mineral supplement with or without choline supplement
Study NCT01980589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
Study NCT01980589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
Study NCT01980589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Study NCT00386542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxigrip® trivalent inactivated influenza vaccine
Description: See full description elsewhere in this record.
Study NCT00386542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip® trivalent inactivated influenza vaccine
Description: See full description elsewhere in this record.
Study NCT00386542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal spacer on Biojector® 2000 jet injector
Description: See elsewhere in this record for full description.
Study NCT03273218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tiger catheter
Study NCT03273218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Judkins catheter
Study NCT04066075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Low Vision Rehabilitation for use of magnification devices for near reading tasks
Study NCT04066075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Vision Rehabilitation
Description: Low Vision Rehabilitation for use of magnification devices for near reading tasks
Study NCT02711280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study NCT02711280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT01526083 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lacosamide
Description: Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
Study NCT01526083 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Warfarin
Description: Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose
Study NCT02797002 — intervention group
Intervention type: OTHER
Intervention: Assessment
Study NCT03998839 — intervention group
Intervention type: OTHER
Intervention: Community distribution of Sulfadoxine-pyrimethamine (SP)
Description: Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
Study NCT00848562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Oral administration of nicorandil (15 mg/day)
Study NCT02166944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tamoxifen 40 mg daily for one year
Description: both arms with riluzole daily
Study NCT02166944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen 40 mg daily for one year
Description: both arms with riluzole daily
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Roll-in
Description: Proctored entry.
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Surgical
Description: Surgery
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Risk
Description: Standard Endovascular repair
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High Risk
Description: High Risk Endovascular repair.
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compassionate Use
Description: Endovascular repair for compassionate use patients.
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment for females
Description: Endovascular repair in female patients
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Risk Continued Access
Description: Continued Access Endovascular repair for standard risk patients.
Study NCT00196092 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High Risk Continued Access
Description: Continued Access Endovascular Repair for High Risk Patients.
Study NCT01538238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: pazopanib 800mg qd until progression or unacceptable toxicity
Study NCT04257760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care consultation outside standard of care
Description: The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
Study NCT00851071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Three 45 minute CBT sessions scheduled over a 3 month period.
Study NCT01384214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: 750 U at Visit 1
Study NCT02307370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbo-Elite Laser Catheter
Description: Application of laser energy to remove blockage
Study NCT01744132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aim 3: Contract
Study NCT00171860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT03737773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glasses (prismatic lenses)
Study NCT00357760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: Given IV
Study NCT03737773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glasses (neutral)
Study NCT01187537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Nerve Block
Description: 20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
Study NCT01187537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Femoral Nerve Block
Description: 20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
Study NCT01827384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given by mouth (PO)
Study NCT01827384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given intravenous (IV)
Study NCT01827384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given by mouth (PO)
Study NCT01827384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given by mouth (PO)
Study NCT01827384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given by mouth (PO)
Study NCT01827384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given by mouth (PO)
Study NCT00667615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
Description: Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
Study NCT01602588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg bd from 14 days post surgery until clinical or radiological progression
Study NCT01602588 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Short Course radiotherapy
Study NCT02019485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)
Description: Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
Study NCT02019485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged-Release Formulation 2 (PR2)
Description: Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
Study NCT03030846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise
Description: 18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
Study NCT03030846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: 8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
Study NCT00732719 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs
Study NCT00732719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Study NCT01654679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wIRA irradiation
Description: wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
Study NCT01654679 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: visible light only
Description: visible light application at a distance of 27cm from the skin surface with for 20 min.
Study NCT00004156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1-KLH vaccine/QS21
Study NCT03570112 — intervention group
Intervention type: DRUG
Intervention: SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
Description: sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
Study NCT04345445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: IV infusion
Study NCT04345445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: IV infusion
Study NCT02670265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olimel Peri 2.5% ®
Description: During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
Study NCT02670265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic fluid (E153)
Description: Controls received 1l of isotonic fluid daily by intravenous route.
Study NCT01617941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Study NCT01617941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
Study NCT00429585 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: reamed, interlocking intramedullary nail
Description: Standard of care device for tibia fracture repair; Randomized Treatment - Nail
Study NCT00429585 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: locking periarticular plate
Description: Standard of care device for tibia fracture repair; Randomized Treatment - Plate
Study NCT03639948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous solution
Study NCT03639948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous solution
Study NCT03639948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous solution
Study NCT03639948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Injectable product
Study NCT03024775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat flour
Description: Wheat flour will be administered three times per day for 15 days.
Study NCT03024775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (xylose) will be administered three times per day for 15 days.
Study NCT01080885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Busy Bodies/Better Bites
Description: This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
Study NCT01080885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Spots/Safe Tots
Description: This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
Study NCT04880928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eye injection (Mydrane)
Description: Mydrane 0.2 mg/ml + 3.1 mg/ml~+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride
Study NCT04880928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eye drops (Phenylephrin)
Description: Phenylephrine 10%
Study NCT04880928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eye drops (Tropicamid)
Description: Tropicamid 0,5%
Study NCT03849339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug
Study NCT03849339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D635
Description: Reference drug
Study NCT02709538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301 NS
Description: FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
Study NCT02709538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS pH 3.7
Description: 2 spray in each nostril twice daily for 52 weeks
Study NCT02709538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS pH 7.0
Description: 2 spray in each nostril twice daily for 52 weeks
Study NCT02343549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF100A
Study NCT02343549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02343549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide